Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

Lenacapavir is an antiretroviral medicine that helps prevent 99.9 per cent of all HIV transmission, according to studies.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

The U.S. Food and Drug Administration has approved a new HIV prevention medication that's been found to be highly effective.

The United States has approved a twice-a-year jab that almost entirely protects against HIV in what’s being hailed as a ...